The Ted Rogers Centre for Heart Research is thrilled to welcome Dr. Cedric Manlhiot as the inaugural Rogers Innovator of Cardiovascular Precision Medicine at SickKids. In addition to his role at TRCHR, Dr. Manlhiot will be a Scientist in the Translational Medicine...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Launching in March 2024, emergency department (ED) physicians at the University Health Network (UHN) can now access the Emergency Heart Failure Mortality Risk Grade (EHMRG) calculator within Epic, UHN’s electronic medical record. The EHMRG score estimates the risk of...
Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
Combing Ontario patient data to find new patterns in heart failure care
Canada’s largest meeting on heart failure is coming this May
Studying the hearts of zebrafish may lead to key HF discoveries
These new online tools may reduce HF hospitalizations
What scarless tissue repair could mean for human hearts
How sick children could save their family members
“We are in uncharted territory”
Providing the best possible care to patients and families
Ground-breaking work underway using CRISPR
ExAC used to reassess pathogenicity of Mendelian disease
